Jonathan Mark Hopper - 02 Dec 2025 Form 4 Insider Report for Vericel Corp (VCEL)

Reporting relationship: Chief Medical Officer
Issuer ticker: VCEL
Reported as of: 02 Dec 2025
Net transaction value: -$34,923
SEC form: 4
Accepted by SEC: 04 Dec 2025, 16:05:33 UTC
Prior SEC filing: 03 Sep 2025
Next SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper

Key filing fact

Jonathan Mark Hopper filed Form 4 for Vericel Corp (VCEL) on 04 Dec 2025.

Key facts

This page summarizes Jonathan Mark Hopper's Form 4 filing for Vericel Corp (VCEL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Dec 2025, 16:05.

Change

Previous filing in this sequence was filed on 03 Sep 2025.
Current net transaction value: -$34,923.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001626325 Primary reporting owner

Hopper Jonathan Mark

Relationship: Chief Medical Officer
Address: 64 SIDNEY STREET, CAMBRIDGE
Signature: /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Signature date: 04 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VCEL transaction

Common Stock

Options Exercise

Transaction value: $29,736
Shares: +1,652
Change %: +2.5%
Price: $18.00
Shares after: 68,214
Date: 02 Dec 2025
Ownership: Direct
Footnotes: F1

VCEL transaction

Common Stock

Sale

Transaction value: $64,659
Shares: -1,652
Change %: -2.4%
Price: $39.14
Shares after: 66,562
Date: 02 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VCEL transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: +1,652
Change %: +30%
Price: $0.000000
Shares after: 7,098
Date: 02 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,652
Exercise price: $18.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Footnote F2

The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025.

Footnote F3

These options, representing the right to purchase 48,750 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 11, 2020.